Alzheimer Society applauds House of Commons motion calling on government to address dementia in Canada

The Alzheimer Society of Canada applauds a motion passed Friday by the House of Commons calling on the Federal Government to "address the rising financial and human costs of Alzheimer's disease and other forms of dementia in Canada."

"This is great news for Canadians," says Debbie Benczkowski, CEO, Alzheimer Society of Canada. "This motion is the first step towards a much needed National Brain Strategy. Federal support and recognition of the scope of the problem means we have the potential to improve the lives of more than 500,000 Canadians diagnosed with Alzheimer's disease or a related dementia."

According to the Alzheimer Society's recent report, Rising Tide: The Impact of Dementia on Canadian Society, someone in Canada develops dementia every five minutes. In a generation, this will increase to a new case every two minutes. If nothing changes, this sharp increase in the number of people living with dementia will mean that by 2038, the total costs associated with dementia will reach $153 billion a year. This amounts to a massive cumulative total of $872 billion over a 30-year period."

Benczkowski adds that she was heartened to see all parties come together to support the motion tabled by James Rajotte, Conservative MP for Edmonton-Leduc. "Alzheimer's disease touches so many people and causes immeasurable distress for Canadian families."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common cardiovascular drugs linked to lower risk of dementia